Cargando…

A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test

Background: There are several mechanisms to describe allergic drug reactions yet the methods to diagnose them are limited. Objective: To compare several conventional clinical and laboratory methods to diagnose skin reactions to drugs to a new method of diagnosing drug reactions by the CellScan syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Ilan, Gilburd, Boris, Kravitz, Martine Szyper, Kivity, Shmuel, Ben Chaim, Berta, Klein, Tirza, Schiffenbauer, Yael, Trubniykovr, Ela, Brenner, Sarah, Shoenfeld, Yehuda
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270720/
https://www.ncbi.nlm.nih.gov/pubmed/15712603
http://dx.doi.org/10.1080/10446670410001722230
_version_ 1782151746611576832
author Goldberg, Ilan
Gilburd, Boris
Kravitz, Martine Szyper
Kivity, Shmuel
Ben Chaim, Berta
Klein, Tirza
Schiffenbauer, Yael
Trubniykovr, Ela
Brenner, Sarah
Shoenfeld, Yehuda
author_facet Goldberg, Ilan
Gilburd, Boris
Kravitz, Martine Szyper
Kivity, Shmuel
Ben Chaim, Berta
Klein, Tirza
Schiffenbauer, Yael
Trubniykovr, Ela
Brenner, Sarah
Shoenfeld, Yehuda
author_sort Goldberg, Ilan
collection PubMed
description Background: There are several mechanisms to describe allergic drug reactions yet the methods to diagnose them are limited. Objective: To compare several conventional clinical and laboratory methods to diagnose skin reactions to drugs to a new method of diagnosing drug reactions by the CellScan system. Methods: The study entailed 21 patients who were diagnosed as suffering from drug eruptions, and 105 healthy controls with no history of drug allergy. The drugs were classified into two groups according to suspicion of causing drug allergy: high and low. Most of the patients were on more than one drug, leading to 41 patient-drug interactions (assays). Histamine releasing test (HRT), interferon (INF)-γ releasing test and CellScan examination were performed on lymphocytes of the patients and controls. Results: The HRT was interpreted as positive in 9 out of 18 (50%) patients and in 13 out of 35 (37%) assays. Based on the INF-γ releasing test, positive results were observed in 16 out of 21 (76%) patients and in 24 out of 41 (59%) assays. In the CellScan test (CST), positive results were observed in 17 out of 21 (81%) patients and in 29 out of 41 (71%) assays. The rate of identifying the drug for eruption in the high suspicion level drugs was 9 out of 22 (41%) assays in the HRT, 20 out of 24 (83%) assays in the INF-γ releasing test, and 21 out of 24 (87%) studies with the CellScan method. The rate of determining of the drug that caused the eruption in the low suspicion level drugs was 4 out of 13 (31%) in the HRT, 4 out of 17 (24%) assays in the INF-γ releasing test, and 8 out of 17 (47%) analyses in the CST. When examined in the CellScan, 99 out of 105 (94%) controls were interpreted as negative. Conclusion: This preliminary study indicates that the CellScan seems to be an easy and promising method for the detection of drugs responsible for adverse skin reactions. In contrast to the HRT and to the Interferon-γ secretion test, the CellScan method is characterized by its ability to track and monitor the reaction of individual cells. By measuring the kinetic parameters of selected cells before and after adding the suspected drug, we were able to identify the culprit drug. The CellScan method had the highest sensitivity, and the interferon-γ secretion test had the highest specificity for detection of the culprit drug. In contrast, the analysis of 105 normal control sera disclosed a high specificity of 94% for the CellScan method.
format Text
id pubmed-2270720
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-22707202008-03-31 A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test Goldberg, Ilan Gilburd, Boris Kravitz, Martine Szyper Kivity, Shmuel Ben Chaim, Berta Klein, Tirza Schiffenbauer, Yael Trubniykovr, Ela Brenner, Sarah Shoenfeld, Yehuda Clin Dev Immunol Research Article Background: There are several mechanisms to describe allergic drug reactions yet the methods to diagnose them are limited. Objective: To compare several conventional clinical and laboratory methods to diagnose skin reactions to drugs to a new method of diagnosing drug reactions by the CellScan system. Methods: The study entailed 21 patients who were diagnosed as suffering from drug eruptions, and 105 healthy controls with no history of drug allergy. The drugs were classified into two groups according to suspicion of causing drug allergy: high and low. Most of the patients were on more than one drug, leading to 41 patient-drug interactions (assays). Histamine releasing test (HRT), interferon (INF)-γ releasing test and CellScan examination were performed on lymphocytes of the patients and controls. Results: The HRT was interpreted as positive in 9 out of 18 (50%) patients and in 13 out of 35 (37%) assays. Based on the INF-γ releasing test, positive results were observed in 16 out of 21 (76%) patients and in 24 out of 41 (59%) assays. In the CellScan test (CST), positive results were observed in 17 out of 21 (81%) patients and in 29 out of 41 (71%) assays. The rate of identifying the drug for eruption in the high suspicion level drugs was 9 out of 22 (41%) assays in the HRT, 20 out of 24 (83%) assays in the INF-γ releasing test, and 21 out of 24 (87%) studies with the CellScan method. The rate of determining of the drug that caused the eruption in the low suspicion level drugs was 4 out of 13 (31%) in the HRT, 4 out of 17 (24%) assays in the INF-γ releasing test, and 8 out of 17 (47%) analyses in the CST. When examined in the CellScan, 99 out of 105 (94%) controls were interpreted as negative. Conclusion: This preliminary study indicates that the CellScan seems to be an easy and promising method for the detection of drugs responsible for adverse skin reactions. In contrast to the HRT and to the Interferon-γ secretion test, the CellScan method is characterized by its ability to track and monitor the reaction of individual cells. By measuring the kinetic parameters of selected cells before and after adding the suspected drug, we were able to identify the culprit drug. The CellScan method had the highest sensitivity, and the interferon-γ secretion test had the highest specificity for detection of the culprit drug. In contrast, the analysis of 105 normal control sera disclosed a high specificity of 94% for the CellScan method. Hindawi Publishing Corporation 2005-03 /pmc/articles/PMC2270720/ /pubmed/15712603 http://dx.doi.org/10.1080/10446670410001722230 Text en Copyright © 2005 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Goldberg, Ilan
Gilburd, Boris
Kravitz, Martine Szyper
Kivity, Shmuel
Ben Chaim, Berta
Klein, Tirza
Schiffenbauer, Yael
Trubniykovr, Ela
Brenner, Sarah
Shoenfeld, Yehuda
A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test
title A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test
title_full A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test
title_fullStr A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test
title_full_unstemmed A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test
title_short A Novel System to Diagnose Cutaneous Adverse Drug Reactions Employing the Cellscan—Comparison with Histamine Releasing Test and Inf-γ Releasing Test
title_sort novel system to diagnose cutaneous adverse drug reactions employing the cellscan—comparison with histamine releasing test and inf-γ releasing test
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270720/
https://www.ncbi.nlm.nih.gov/pubmed/15712603
http://dx.doi.org/10.1080/10446670410001722230
work_keys_str_mv AT goldbergilan anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT gilburdboris anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT kravitzmartineszyper anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT kivityshmuel anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT benchaimberta anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT kleintirza anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT schiffenbaueryael anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT trubniykovrela anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT brennersarah anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT shoenfeldyehuda anovelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT goldbergilan novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT gilburdboris novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT kravitzmartineszyper novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT kivityshmuel novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT benchaimberta novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT kleintirza novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT schiffenbaueryael novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT trubniykovrela novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT brennersarah novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest
AT shoenfeldyehuda novelsystemtodiagnosecutaneousadversedrugreactionsemployingthecellscancomparisonwithhistaminereleasingtestandinfgreleasingtest